Outcomes of Intercalary Endoprostheses as a Treatment for
Metastases in the Femoral and Humeral Diaphysis

J 2022

Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis

MAHDAL, Michal; Lukáš PAZOUREK; Vasileios APOSTOLOPOULOS; Dagmar ADÁMKOVÁ KRÁKOROVÁ; Iva STANICZKOVÁ ZAMBO et al.

Základní údaje

Originální název

Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis

Autoři

MAHDAL, Michal; Lukáš PAZOUREK; Vasileios APOSTOLOPOULOS; Dagmar ADÁMKOVÁ KRÁKOROVÁ; Iva STANICZKOVÁ ZAMBO a Tomáš TOMÁŠ

Vydání

CURRENT ONCOLOGY, Basel, MDPI, 2022, 1198-0052

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30204 Oncology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.600

Označené pro přenos do RIV

Ano

Kód RIV

RIV/00216224:14110/22:00127136

Organizační jednotka

Lékařská fakulta

Klíčová slova anglicky

bone neoplasm; metastasis; diaphysis of long bones; intercalary endoprosthesis

Štítky

14110112, 14110123, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 25. 1. 2023 10:05, Mgr. Tereza Miškechová

Anotace

V originále

The purpose of this study was to evaluate the implant survival, functional score and complications of intercalary endoprostheses implanted for metastatic involvement of the femoral and humeral diaphysis. The mean follow-up was 29.8 months. In our group of 25 patients with 27 intercalary endoprostheses (18 femurs, 9 humeri), there were 7 implant-related complications (25.9%), which were more common on the humerus (4 cases, 44.4%) than on the femur (3 cases, 16.7%). Only type II failure—aseptic loosening (5 cases, 18.5%)—and type III failure—structural failure (2 cases, 7.4%)—occurred. There was a significantly higher risk of aseptic loosening of the endoprosthesis in the humerus compared with that in the femur (odds ratio 13.79, 95% confidence interval 1.22–151.05, p = 0.0297). The overall cumulative implant survival was 92% 1 year after surgery and 72% 5 years after surgery. The average MSTS score was 82%. The MSTS score was significantly lower (p = 0.008) in the humerus (75.9%) than in the femur (84.8%). The resection of bone metastases and replacement with intercalary endoprosthesis has excellent immediate functional results with an acceptable level of complications in prognostically favourable patients.

Citovat

MAHDAL, Michal; Lukáš PAZOUREK; Vasileios APOSTOLOPOULOS; Dagmar ADÁMKOVÁ KRÁKOROVÁ; Iva STANICZKOVÁ ZAMBO a Tomáš TOMÁŠ. Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis. CURRENT ONCOLOGY. Basel: MDPI, 2022, roč. 29, č. 5, s. 3519-3530. ISSN 1198-0052. Dostupné z: https://doi.org/10.3390/curroncol29050284.

@article{2231013,
   author = {Mahdal, Michal and Pazourek, Lukáš and Apostolopoulos, Vasileios and Adámková Krákorová, Dagmar and Staniczková Zambo, Iva and Tomáš, Tomáš},
   article_location = {Basel},
   article_number = {5},
   doi = {https://doi.org/10.3390/curroncol29050284},
   keywords = {bone neoplasm; metastasis; diaphysis of long bones; intercalary endoprosthesis},
   language = {eng},
   issn = {1198-0052},
   journal = {CURRENT ONCOLOGY},
   title = {Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis},
   url = {http://www.mdpi.com/1718-7729/29/5/284/htm},
   volume = {29},
   year = {2022}
}

TY  - JOUR
ID  - 2231013
AU  - Mahdal, Michal - Pazourek, Lukáš - Apostolopoulos, Vasileios - Adámková Krákorová, Dagmar - Staniczková Zambo, Iva - Tomáš, Tomáš
PY  - 2022
TI  - Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis
JF  - CURRENT ONCOLOGY
VL  - 29
IS  - 5
SP  - 3519-3530
EP  - 3519-3530
PB  - MDPI
SN  - 11980052
KW  - bone neoplasm
KW  - metastasis
KW  - diaphysis of long bones
KW  - intercalary endoprosthesis
UR  - http://www.mdpi.com/1718-7729/29/5/284/htm
N2  - The purpose of this study was to evaluate the implant survival, functional score and complications of intercalary endoprostheses implanted for metastatic involvement of the femoral and humeral diaphysis. The mean follow-up was 29.8 months. In our group of 25 patients with 27 intercalary endoprostheses (18 femurs, 9 humeri), there were 7 implant-related complications (25.9%), which were more common on the humerus (4 cases, 44.4%) than on the femur (3 cases, 16.7%). Only type II failure—aseptic loosening (5 cases, 18.5%)—and type III failure—structural failure (2 cases, 7.4%)—occurred. There was a significantly higher risk of aseptic loosening of the endoprosthesis in the humerus compared with that in the femur (odds ratio 13.79, 95% confidence interval 1.22–151.05, p = 0.0297). The overall cumulative implant survival was 92% 1 year after surgery and 72% 5 years after surgery. The average MSTS score was 82%. The MSTS score was significantly lower (p = 0.008) in the humerus (75.9%) than in the femur (84.8%). The resection of bone metastases and replacement with intercalary endoprosthesis has excellent immediate functional results with an acceptable level of complications in prognostically favourable patients.
ER  -

MAHDAL, Michal; Lukáš PAZOUREK; Vasileios APOSTOLOPOULOS; Dagmar ADÁMKOVÁ KRÁKOROVÁ; Iva STANICZKOVÁ ZAMBO a Tomáš TOMÁŠ. Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Femoral and Humeral Diaphysis. \textit{CURRENT ONCOLOGY}. Basel: MDPI, 2022, roč.~29, č.~5, s.~3519-3530. ISSN~1198-0052. Dostupné z: https://doi.org/10.3390/curroncol29050284.

Přehled o publikaci